Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;17(1):7-13.
doi: 10.2174/0118744710262325231025075638.

Astatine-211 Radiopharmaceuticals; Status, Trends, and the Future

Mobina Rabiei  1 , Mahboobeh Asadi  2 , Hassan Yousefnia  3
Affiliations
Free article
Review

Astatine-211 Radiopharmaceuticals; Status, Trends, and the Future

Mobina Rabiei et al. Curr Radiopharm. 2024.
Free article

Abstract

The low range of alpha particles provides an opportunity to better target cancer cells theoretically leading to the introduction of interesting alpha emitter radiopharmaceuticals including 225Ac, 212Pb, etc. The combination of high energy and short range of alpha emitters differentiates targeted radiotherapy from other methods and reduces unwanted cytotoxicity of the cells around the tumoral tissue. Among interesting alpha emitters candidates for targeted therapy, 211At, one of the radioisotopes with the best optimal decay properties, shows great promise for targeted radiotherapy in some animal prostate cancer xenograft studies and bone micro tumors with significant effects compared to other beta and alpha emitters and also demonstrates interesting properties for clinical applications. However, production and application of this alpha emitter in the development of actinium-based radiopharmaceuticals is hampered by many obstacles. This mini-review demonstrates 211At production methods, chemical separation, radiolabeling procedures, 211At-radiopharmaceuticals and their clinical trials, transport, logistics, and costs and future trends in the field for ultimate clinical applications. This review showed that there are limited clinical trials on 211Ac-based radiopharmaceuticals, which is due to the low accessibility of this radioisotope and other limitations. However, the development programs of major industries indicate the development of 211Ac-based radiopharmaceuticals in the future.

Keywords: Alpha emitter; astatine-211; production of 211At; radioisotopes; radiolabeling; radiopharmaceuticals..

PubMed Disclaimer

References

    1. Zalutsky M.R.; Pruszynski M.; Astatine-211: Production and availability. Curr Radiopharm 2011,4(3),177-185 - DOI - PubMed
    1. Leidermark E.; Hallqvist A.; Jacobsson L.; Karlsson P.; Holmberg E.; Bäck T.; Johansson M.; Lindegren S.; Palm S.; Albertsson P.; Estimating the risk for secondary cancer after targeted a-therapy with 211at intraperitoneal radioimmunotherapy. J Nucl Med 2023,64(1),165-172 - DOI - PubMed
    1. Radchenko V.; Morgenstern A.; Jalilian A.R.; Ramogida C.F.; Cutler C.; Duchemin C.; Hoehr C.; Haddad F.; Bruchertseifer F.; Gausemel H.; Yang H.; Osso J.A.; Washiyama K.; Czerwinski K.; Leufgen K.; Pruszyński, M.; Valzdorf, O.; Causey, P.; Schaffer, P.; Perron, R.; Maxim, S.; Wilbur, D.S.; Stora, T.; Li, Y. Production and supply of a-particle-emitting radionuclides for targeted A-Therapy. J Nucl Med 2021,62(11),1495-1503 - DOI - PubMed
    1. Burns J.D.; Tereshatov E.E.; Avila G.; Glennon K.J.; Hannaman A.; Lofton K.N.; Mccann L.A.; Mccarthy M.A.; Mcintosh L.A.; Rapid recovery of At-211 by extraction chromatography. Separ Purif Tech 2021,256,117794
    1. Burns J.D.; Tereshatov E.E.; McCarthy M.A.; McIntosh L.A.; Tabacaru G.C.; Yang X.; Hall M.B.; Yennello S.J.; Astatine partitioning between nitric acid and conventional solvents: Indication of covalency in ketone complexation of AtO +. Chem Commun 2020,56(63),9004-9007 - DOI - PubMed